接受手术的淋巴结阳性非小细胞肺癌患者指南一致性治疗的差异
该研究基于美国国家癌症数据库2006至2013年数据,纳入13462例接受肺叶或全肺切除、切缘阴性、未行新辅助治疗的pT1-3 N1-2 M0非小细胞肺癌患者,评估指南一致性辅助治疗的使用差异。结果显示pN1和pN2患者中分别有67.7%和78.3%接受了指南一致性治疗,保险状态、年龄、手术方式等因素与治疗一致性相关。
要点
- pN1和pN2患者指南一致性辅助治疗率分别为67.7%和78.3%。
- 保险状态、高龄、全肺切除、再入院和术后住院时间长与指南一致性治疗可能性降低相关。
- 接受指南一致性治疗的患者5年生存率显著优于未接受者(51.6% vs 36.0%)。
核心结论
- 社会经济因素(包括保险状态和地理区域)与NCCN指南推荐的辅助治疗使用差异相关,并显著影响患者生存。
研究设计与样本
- 回顾性队列研究,纳入美国国家癌症数据库2006至2013年间13462例接受肺叶或全肺切除、切缘阴性、未行新辅助治疗的pT1-3 N1-2 M0非小细胞肺癌患者。
主要发现
- pN1患者中6844例(67.7%)接受了指南一致性辅助治疗,pN2患者中2622例(78.3%)接受了指南一致性辅助治疗。
- 多因素校正后,保险状态、高龄、全肺切除、再入院和较长术后住院时间与指南一致性治疗可能性降低相关;较高教育水平、较晚诊断年份和较高淋巴结分期与更高一致性相关。
关键数值与推荐
- 指南一致性辅助治疗定义为pN1疾病接受化疗,pN2疾病接受化疗伴或不伴放疗。
临床怎么用
- 临床应关注保险状态和社会经济弱势群体,提高指南一致性辅助治疗的可及性以改善生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To examine guideline concordance across a national sample and determine the relationship between socioeconomic factors, use of recommended postoperative adjuvant therapy, and outcomes for patients with resected pN1 or pN2 non-small cell lung cancer. METHODS: All margin-negative pT1-3 N1-2 M0 non-small cell lung cancers treated with lobectomy or pneumonectomy without induction therapy in the National Cancer Database between 2006 and 2013 were included. Use of guideline-concordant adjuvant treatment, defined as chemotherapy for pN1 disease and chemotherapy with or without radiation for pN2 disease, was examined. Multivariable regression models were developed to determine associations of clinical factors with guideline adherence. Survival was estimated using Kaplan-Meier and Cox proportional hazard analyses. RESULTS: Of 13,462 patients, 10,113 had pN1 disease and 3349 had pN2 disease. Guideline-concordant adjuvant therapy was used in 6844 (67.7%) patients with pN1 disease and 2622 (78.3%) patients with pN2 disease. After multivariable adjustment, insurance status, older age, pneumonectomy, readmission, and longer postoperative stays were associated with lower likelihood of guideline concordance. Conversely, increased education level, later year of diagnosis, and greater nodal stage were associated with greater concordance. Overall, patients treated with guideline-concordant therapy had superior survival (5-year survival: 51.6 vs 36.0%; hazard ratio, 0.66; 95% confidence interval, 0.62-0.70, P < .001). CONCLUSIONS: Socioeconomic factors, including insurance status and geographic region, are associated with disparities in use of adjuvant therapy as recommended by National Comprehensive Cancer Network guidelines. These disparities significantly impact patient survival. Future work should focus on improving access to appropriate adjuvant therapies among the under insured and socioeconomically disadvantaged.
引用
- Farrow NE, An SJ, Speicher PJ, et al. Disparities in guideline-concordant treatment for node-positive, non-small cell lung cancer following surgery. J Thorac Cardiovasc Surg. 2019. PMID: 31924363. doi:10.1016/j.jtcvs.2019.10.102
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。